Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease

INTRODUCTION: Roflumilast is a phosphodiesterase-4 inhibitor, which can decrease exacerbation in patients with chronic obstructive pulmonary disease (COPD). However, adverse effects are a major barrier to medication use, and little is known regarding the risk factors for discontinuation of roflumila...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Int J Chron Obstruct Pulmon Dis
Hoofdauteurs: Kim, Kyung Hoon, Kang, Hye Seon, Kim, Ju Sang, Yoon, Hyoung Kyu, Kim, Sung Kyoung, Rhee, Chin Kook
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove Medical Press 2017
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720347/
https://ncbi.nlm.nih.gov/pubmed/29270006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S143967
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items